Spain's Pharma Deficit Eats Savings

13 March 1995

The exclusion of 1,658 medicines from reimbursement in 1994 in Spain brought about a saving to the country's social security of 22.3 billion pesetas ($173.4 million). However, this saving has been totally absorbed by the social security pharmaceutical deficit, which exceeded by around 20.3 billion pesetas the initial budget of 217.6 billion pesetas for 1994.

Savings on pharmaceutical spending were also derived from the agreement between the country's pharmaceutical companies and the government to a 3% price reduction for medicines. This brought in a saving of around 47.4 billion pesetas. The measure did not prevent the pharmaceutical industry from growing 4.7% last year, with turnover of around 534.9 billion pesetas ($4.1 billion), 394.4 billion pesetas of which was financed by social security.

The second means of saving was directly through pharmacies, which made discounts of between 1.3% and 2%, bringing in a saving of 5.1 billion pesetas. In real terms the saving was 27.1 billion pesetas, with a pharmaceutical deficit of 237.8 billion pesetas, reports the Spanish financial daily newspapers Cinco Dias.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight